← Russell 3000 cross-section

OFIX Orthofix Medical Inc.

Trailing twelve months to 2026-06-30 · as filed 2026-08-05, not restated
Healthcare

Scale

Market cap
$400m
Revenue TTM
$833m
Net income TTM
$-62m
Free cash flow
$-28m
Composite score
28.7
Sector rank
#2511

Valuation

P / E
EV / EBITDA
37.9
EV / sales
0.6
FCF yield
-6.96%
Earnings yield vs 10-yr
-20.16pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-7.4%
EBITDA margin
1.6%
ROE
-14.4%
ROIC
-7.2%
Revenue growth
3.0%

Insider activity, last 90 days

Net open-market
$-0.45m
Buyers
0
Sellers
3

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

Spinal Implants, Biologics, and Enabling Technologies products are sold through a network of distributors and sales representatives to hospitals and healthcare providers on a global basis for Spinal Implants and Enabling Technologies, and primarily within the U.S. for Biologics. Earnings per share (EPS) For the three and six months ended June 30, 2026 , no adjustments were made to net income for purposes of calculating basic and diluted EPS under the treasury stock method. …Orthofix Medical Inc., 10-Q, period ended 2026-06-30, filed 2026-08-05

Read the full passage →